Home
Site Search
Use small fonts Use medium fonts Use large fonts Email link to page

Resources

Related expertise

Theralase Completes $17.25 Million Prospectus Offering

Published: 08/22/2019

Team: Andrea FitzGerald, Nancy Choi, Jasmine Qin, Christopher B. Norton

On August 22, 2019, Theralase Technologies Inc. completed a short form prospectus offering pursuant to which 57,500,000 units of Theralase were issued (including the exercise in full of the over-allotment option) at a price of $0.30 per unit for gross proceeds of $17.25 million. Each unit consisted of one common share and one common share purchase warrant of Theralase. Each warrant shall be exercisable to acquire one common share at a price of $0.35 until August 22, 2024.

Cassels Brock acted for Theralase with a deal team that included Andrea FitzGerald, Nancy Choi and Jasmine Qin (Securities) and Chris Norton (Tax).